Related Experiment Video
Updated: Dec 21, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Why Do the Majority of Submissions for Bridging from a Prefilled Syringe to an Autoinjector Include Bioequivalence
1Module 3 Pharmaceutical Consulting, PO Box 3032, Incline Village, Nevada, 89450, USA. pharmsci.BL@gmail.com.
Abstract:
A recent paper reviewed clinical studies intending to bridge a prefilled syringe (PFS) to an autoinjector (AI) based on regulatory submission packages sent to the FDA. An AI generally uses the identical PFS within the AI and the AI typically results in a more consistent injection than can be achieved with a PFS. It is noted that several studies submitted to the FDA did not demonstrate bioequivalence (BE) between the PFS and AI, yet the products were approved anyway. The author of this Commentary believes that formal BE studies should not be required for such bridging studies.
Related Concept Videos
Bioequivalence studies: Biowaivers
Bioequivalence: Overview
Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence of Drugs: Drugs with Multiple Indications
Pharmaceutical Equivalents
Drug Products: Biologics, Biosimilars and Interchangeables

